Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2080174 | Drug Discovery Today | 2010 | 8 Pages |
Abstract
It has been predicted that the use of non-human primates (NHPs) is going to increase considerably in the development of monoclonal antibodies (mAbs). Opportunities exist to focus on a rigorous, science-based approach to drug development, however, which will minimize this increase. In this article, the authors review current and future NHP use in mAb development based on surveys, experience and expert opinion and propose a framework that will minimize future NHP use and continue to support science and innovation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Kathryn L. Chapman, Nick Pullen, Laura Andrews, Ian Ragan,